While the global industry tries to harmonize via the ICH Q4B process, differences remain.
The European Pharmacopoeia does not exist in isolation. To reduce redundancy and facilitate global drug development, the Ph. Eur. works closely with the and the Japanese Pharmacopoeia (JP) through the Pharmacopoeial Discussion Group (PDG) and the ICH Q4B process. This collaboration aims to harmonize key general chapters.
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Revised Ph. Eur. Chapter Tablets - ECA Academy European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
The active substance(s) must be identified using the tests prescribed in the specific monograph for that substance (e.g., spectroscopy, chromatography).
While not always a specific limit in the monograph, hardness is a critical in-process control (IPC). The tablet must be hard enough to handle but soft enough to disintegrate/dissolve. While the global industry tries to harmonize via
: For tablets with break-marks, the efficacy of the mark is assessed by weighing subdivided parts. Not more than one out of 30 parts may fall outside 85% to 115% of the average mass. 4. Mandatory Pharmacopoeial Tests
A soft tablet (low hardness) might disintegrate in 12 minutes, but a hard tablet (high compression force) might take 25 minutes, failing 0478. Formulators must balance hardness and disintegration. This is for informational purposes only
Use Ph. Eur. Monograph 0478 as your minimum quality standard for uncoated and film-coated immediate-release tablets. For regulatory submissions (e.g., CEP, DMF, or marketing authorization in Europe), you must comply with it. However, to achieve robust product quality, supplement it with:
These are designed to release the active substance(s) at a defined time or over an extended period.
European Pharmacopoeia (Ph. Eur.) Monograph 0478 establishes essential quality standards for oral tablets, covering classification, uniformity of dosage, and disintegration, with specific requirements for scored tablet functionality. The monograph mandates strict tests for uniformity of content (Chapter 2.9.6) and mass (Chapter 2.9.5), along with specific criteria for break-mark functionality, requiring 85%–115% uniformity for fractional doses. For further detailed technical guidance, professionals can refer to the official EDQM Knowledge Base gmp-compliance.org
: A test to determine how the active substance is released into a solvent over time, ensuring the drug will be available for absorption in the body. Mechanical Strength :